eHealth mHealth HealthTech innovations - Marketing Santé innovant
43.2K views | +17 today
Follow
 
Scooped by Dominique Godefroy
onto eHealth mHealth HealthTech innovations - Marketing Santé innovant
Scoop.it!

Diagnosing and Treating Depression with AI and Machine Learning

Diagnosing and Treating Depression with AI and Machine Learning | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it

Depression is a leading mental disorder impacting about 16 million Americans. According to the World Health Organization, the annual global economic impact of depression is estimated at $1 trillion and is projected to be the leading cause of disability by 2020.

As researchers aim to better predict, diagnose and treat depression, artificial intelligence is being explored as a potential solution.

Some of the questions that need answering to better understand the role of artificial intelligence in efforts to diagnose and treat depression:

- What types of AI applications are currently in use to manage depression?
- How has the market responded to these AI applications?
- Are there any common trends among these innovation efforts – and how could these trends possibly contribute to reducing the rates of people living with depression?

more...
No comment yet.
eHealth mHealth HealthTech innovations - Marketing Santé innovant
Digital, Apps, IoT, devices, AI / DL (...) innovations for Health and Healthcare
Your new post is loading...
Your new post is loading...
Scooped by Dominique Godefroy
Scoop.it!

How AI is making its way into pharma and healthcare

How AI is making its way into pharma and healthcare | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it

Will we see enhancements of AI in pharma and healthcare?

Having read many insightful articles and spoken to several experts on how artificial intelligence (AI) will significantly impact on the healthcare industry, I wanted to add to the conversation. Specifically, in terms of how advances in voice technology and chatbots will not only enhance patient care but also give pharmaceutical companies access to alternative providers and innovative services to support their brands.

Investment facts and forecasts for AI in pharma and healthcare

It’s easy to think that AI in pharma and healthcare is something that “I don’t need to worry about for a while”, “Doesn’t apply to my brand” or “Will be a while before it takes off”. However, if investment is ever a measure of how serious an industry is about making something happen, then the routine use of AI is already here. This is particularly true in the area of analysing big data to identify trends; with the ultimate goal of natural conversations with AI (‘hybrid AI’ systems) just around the corner.
From an NHS funding perspective, the Academic Health Science Networks (AHSN) and SBRI Healthcare partnership has funded 87 companies with a total of approximately £35 million since 2013 in the digital/ICT/mobile solutions category alone. One specific project in this category related to the use of a chatbot/avatar for supporting young people with mental health conditions, which attracted funding of just over £1 million.

According to McKinsey Global Institute, the funding from the private sector is significant, with internal investment in AI by large corporations estimated to be between $18 billion and $27 billion in 2016 alone, while external investment (from venture capitalists, private equity etc) accounted for $8 billion to $12 billion.

more...
No comment yet.
Scooped by Dominique Godefroy
Scoop.it!

Is emotional support part of AI's future in healthcare?

Is emotional support part of AI's future in healthcare? | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it
The uses for artificial intelligence have been sprouting up all over the healthcare field, from reading images to automating work flows. Now some researchers are looking to use that technology to move beyond the analytical tasks and move into providing a more human touch.

“There is one view that we can allow these AI [tools] to deal with data and analytics and we let people deal with the caring, and the empathy, and the emotional aspects of care, which I think is absolutely critical,” Cynthia Breazeal, associate professor of media arts and sciences at MIT and director of the Personal Robots Group, said at the Connected Health Conference in Boston this morning. “What if technology is capable of high touch engagement? What if AI was also social and emotionally intelligent?”

As Amazon Echos and Google Homes begin to enter the domestic space, the population that comes into contact with AI is growing. Children and senior citizens alike are are now engaging with the technology, she points out. This could make the technology ripe for new uses and a wider audience.

Breazeal’s lab focuses on machines called social robots.

“For me when I talk about emotional engagement, it’s not just about great user experience with technology,” she said. “It is about deeper human engagement to enable transformative change in people’s lives.”
more...
No comment yet.
Scooped by Dominique Godefroy
Scoop.it!

Merck & Co picks Nike exec to be digital transformation leader

Merck & Co picks Nike exec to be digital transformation leader | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it

Merck & Co has appointed Nike’s Jim Scholefield to be its new chief information and digital officer, continuing a trend in pharma to hire in expertise from the consumer world.

Scholefield starts work at the US pharma giant on 29 October and will be responsible for leading Merck & Co's (MSD outside North America) IT and digital strategy, increasingly seen as a vital factor in driving business efficiencies and commercial success.

He will also have oversight of cyber-security – a big issue for the company after a ransomware attack in June 2017 brought the company to a grinding halt.

Scholefield will be part of the company’s executive committee, reflecting how integral the digital transformation drive is to the business.

Currently Nike’s chief information officer, Scholefield led the creation of the sportswear giant’s new enterprise architecture, including the upgrade of critical infrastructure and delivery of state-of-the art cyber-security.

He then championed the digital transformation of Nike, using new technology in order to serve consumers “faster and more personally at scale”. The company launched its customised trainer service several years ago, operating under the slogan “you design it we make it” with a normal turnaround time of 3-5 weeks.

It is this kind of digitally enabled speed and customer focus which the big pharma giants are now all pursuing, as more and more interactions with healthcare professionals go digital.

more...
No comment yet.
Scooped by Dominique Godefroy
Scoop.it!

An App Store for genomics

An App Store for genomics | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it

Oklahoma Sen. Elizabeth Warren made headlines this week by publicizing the results of a DNA ancestry test meant to dispel allegations – particularly from President Donald Trump – that her claims of Native American heritage were fabricated. But while her announcement drew mixed opinions from several quarters, it showcased how important a business genetic testing has become and how much it has grown.

That growth raises an interesting question: In a market dominated by the likes of 23andMe, how does a new entrant distinguish itself from the rest of the pack?

Research indicates that genetic testing – particularly to measure susceptibility to disease – is a big business that’s set to get bigger. According to a report in June by Global Market Insights, the global market is expected to exceed $22 billion by 2024, driven in part by interest in testing for early detection and prevention of cancers and genetic diseases. 23AndMe presents an anecdotal case that illustrates that growth: Last March, the Food and Drug Administration approved a test from the company that detects BRCA1/2 mutations to determine the risk of breast cancer, while in July of this year, it signed a four-year drug-discovery partnership with British drugmaker GlaxoSmithKline.

Into this market steps Helix, a personal genomics firm founded in 2015 and headquartered in San Carlos, California, near San Francisco. The company has seen a steady flow of money come in, announcing in June the final close of a $200 million Series B financing led by Tim Draper’s venture capital firm, DFJ, with participation from founding investors Illumina, Warburg Pincus, Sutter Hill Ventures, Kleiner Perkins Caufield Byers and Mayo Clinic, with Singapore’s Temasek closing out the final portion.

more...
No comment yet.
Scooped by Dominique Godefroy
Scoop.it!

Apple and Zimmer Biomet launch 10,000-patient Apple Watch study in hip and knee surgeries

Apple and Zimmer Biomet launch 10,000-patient Apple Watch study in hip and knee surgeries | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it

Apple and Zimmer Biomet have begun collaborating on a large clinical study that will use an Apple Watch and iPhone app to help prepare and track patients through hip and knee replacement surgeries—with the goal of adding digital health products and active engagement to a new standard of care.

The multiyear trial, which aims to enroll as many as 10,000 participants, will study Zimmer Biomet’s mymobility app and its impacts on recovery and overall costs, by combining patient-reported feedback with heart rate and movement data collected both pre- and postsurgery.

In a statement, Zimmer Biomet President and CEO Bryan Hanson described the project as “one of the largest evidence-gathering clinical studies in orthopedic history.” The company estimates that more than 1 million knee and hip replacements are performed each year in the U.S., with that number expected to more than triple in the next two decades.

The app will remind patients to complete their assigned exercises and deliver educational guidance directly from the watch, with content chosen and prescribed by their surgeon.

In addition, a HIPAA-secure messaging client will allow providers to send texts, pictures or videos to patients to check up on their progress, or answer questions without scheduling an appointment.

“We believe one of the best ways to empower consumers is by giving them the ability to use their health and activity information to improve their own care,” said Jeff Williams, Apple’s chief operating officer.

“We are proud to enable knee and hip replacement patients to use their own data and share it with their doctors seamlessly, so that they can participate in their care and recovery in a way not previously possible through traditional in-person visits,” Williams said.

more...
No comment yet.
Rescooped by Dominique Godefroy from WEARABLES - INSIDABLES - IOT - CONNECTED DEVICES - QUANTIFIEDSELF
Scoop.it!

DFree, a smartphone-connected wearable for incontinence, launches in US  #esante #hcsmeufr

DFree, a smartphone-connected wearable for incontinence, launches in US  #esante #hcsmeufr | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it

San Diego-based Triple W has launched a new wearable connected health monitor in the United States, focused on urinary incontinence. The sensor, called DFree, uses an ultrasound sensor to monitor changes in bladder size. Then proprietary algorithms translate that data into information about when a user should head to the bathroom.

 

“DFree is designed to help individuals with incontinence improve quality of life and enable independence, as well as help reduce the burden for the caregivers,” Atsushi Nakanishi, president and CEO of Triple W, said in a statement. “Whether you want to attend a concert, enjoy an afternoon with your grandkids or help a senior parent or loved one who needs extra time to travel from one place to another — you don’t have to worry about finding a bathroom on time.”

 

Why it matters

Incontinence is a widespread but underreported problem, because of the social stigmas involved. The NIH estimates it affects 500 million people worldwide and US retail sales of adult diapers totaled $2 billion in 2016. That market is only growing as baby boomers age.

Triple W’s product could offer an alternative to diapers or pads for some adults. It’s been in use in senior care facilities in Japan and Europe since 2017, the company says.


Via Florian Morandeau, Lionel Reichardt / le Pharmageek
more...
Florian Morandeau's curator insight, October 17, 1:33 AM

This mHealth sensor, called DFree, uses an ultrasound sensor to monitor changes in bladder size.

Scooped by Dominique Godefroy
Scoop.it!

Novartis lance des laboratoires d’innovation en faveur de la santé numérique

Novartis lance des laboratoires d’innovation en faveur de la santé numérique | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it
Novartis a lancé un réseau de laboratoires d’innovation en matière de santé digitale, baptisé Novartis Biome, pour accélérer son évolution numérique. La société pharmaceutique suisse va également développer une série d’initiatives qui, selon elle, sont conçues pour fournir une rampe d’accès aux start-up qui souhaitent travailler avec elle.

Novartis Biome, dont le premier laboratoire d’innovation est basé à San Francisco, a été cofondé par son directeur général Mohanad Fors et le directeur de l’innovation et de la stratégie Robin Roberts. Selon ce dernier, l’idée est de donner un nouvel élan à l’écosystème des technologies de la santé et de définir une rampe d’accès pour collaborer avec Novartis.


Une solution contribuant à collaborer avec les start-up du secteur

Il est clair que la grande majorité des technologies innovantes ne proviendront pas des grandes sociétés pharmaceutiques. En collaborant avec les start-up et des innovateurs, il est possible de créer quelque chose d’audacieux, durable et évolutif.

more...
No comment yet.
Scooped by Dominique Godefroy
Scoop.it!

David Dronneau : " Le digital est un moyen qui doit être intégré dans un système expert "

David Dronneau : " Le digital est un moyen qui doit être intégré dans un système expert " | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it
David Dronneau conduit des initiatives pour intégrer du digital dans les boites de médicament et les informations qui y sont associées. Par exemple, le eLabeling consiste à digitaliser la notice papier vers le smartphone en y agrégeant des vidéos expliquant la pathologie et son traitement.

En quoi le Digital est-il plus que jamais incontournable dans la médecine connectée?
On assiste aujourd'hui à une convergence des technologies : un capteur connecté installé dans une boite de médicaments peut à la fois relever une température, être traçable et envoyer des informations « patient ». L'industrie pharmaceutique ne vend plus seulement un médicament mais une solution thérapeutique articulée autour du médicament.

Est-ce que le eLabeling concerne tous les médicaments ?
Potentiellement oui mais il est plus important pour certaines catégories de patients, à l'exemple des malvoyants qui sont en demande de notices audio. Certains pays autorisent déjà le positionnement de QR codes sur la boite donnant accès à plus d'informations sur la posologie, les contre-indications et la conservation. Nous voulons aller plus loin en y agrégeant des vidéos expliquant la pathologie et son traitement. Il n'est pas question ici de marketing mais de service rendu au patient.
more...
No comment yet.
Rescooped by Dominique Godefroy from GAFAMS, STARTUPS & INNOVATION IN HEALTHCARE by PHARMAGEEK
Scoop.it!

"DOSSIER Prise de rendez-vous médicaux en ligne" - Comment ça marche ? #esante #hcsmeufr 

"DOSSIER Prise de rendez-vous médicaux en ligne" - Comment ça marche ? #esante #hcsmeufr  | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it

66 Millions d’IMpatients s’est penché de près sur les plateformes de prise de rendez-vous médicaux en ligne. Retrouvez dans le dossier issu de cette enquête les différentes fonctionnalités proposées par ces plateformes ainsi qu’une évaluation des outils les plus performants. Nous nous sommes également intéressés aux questions de confidentialité que pose le recours à ce type de plateforme ainsi qu’aux nouveaux services que certaines d’entre elles travaillent à mettre sur pied.

 

C’est un jeune marché en pleine mutation. La possibilité de prendre rendez-vous en ligne avec son médecin est proposée aux patients depuis environ 5 ans. Aujourd’hui, on compte plus d’une dizaine d’acteurs issus de divers horizons proposant ce type de service.

 

Médecins généralistes ou spécialistes mais aussi dentistes, ostéopathes, kiné ou autres paramédicaux… Ces plateformes, appelons les ainsi, permettent en quelques clics de prendre rendez-vous avec des professionnels de santé exerçant en ville ou bien dans des établissements de santé. L'Assistance publique-Hôpitaux de Paris (AP-HP), par exemple; ou encore le CHU de Nîmes et d'autres hôpitaux de région ont opté pour ce mode de prise de rendez-vous.

Plus d’un Français sur quatre recourt à ce service

Plus d’un quart des patients auraient recours à ce type de service selon un sondage OpinionWay pour MonDocteur, publié au printemps dernier (voir ci-dessous pour plus de détails sur les résultats de ce sondage). On estime par ailleurs qu’environ 15% des professionnels de santé seraient adhérents à l’une ou l’autre de ces plateformes.

 

Doctolib est sans aucun doute la plus connue des patient(e)s. Et pour cause, puisqu’environ 60 000 professionnels et quelque 1 000 établissements proposeraient une prise de rendez-vous en ligne par son intermédiaire. Le site revendique plus de 20 millions de visites par mois.

 

Pour figurer dans le carnet d’adresses de la start-up, les praticiens sont tenus de s’acquitter d’un montant de 109 euros par mois. Le service est gratuit pour les patients. Le modèle économique adopté par les autres plateformes est similaire. Tant mieux pour l'utilisateur : ce mode de financement lui garantie la gratuité et l'absence de publicité. 

Un service mis sur pied avant tout pour les médecins

En 2017, l’Union régionale des professionnels de santé (URPS) d’Île-de-France a publié les résultats d’une étude sur une quinzaine de plateformes visant à fournir aux médecins les outils permettant d’orienter leur choix vers l’un ou l’autre de ces services.

 

« Pour le médecin, gérer efficacement ses rendez-vous est crucial, explique-t-on à l’URPS. Que cette tâche soit assurée par lui-même, son secrétariat ou un télésecrétariat, l’organisation du planning de ses consultations et la présence effective des patients aux rendez-vous constituent des enjeux majeurs de son activité quotidienne. La prise de rendez-vous en ligne transforme l’organisation du travail des médecins ».

 

Ce type de service, pour les plateformes dont les fonctionnalités sont les plus avancées, permet au patient d’accéder en tout temps à l’agenda du médecin et de choisir dans le calme et le confort de son domicile la tranche horaire qui lui convient le mieux. L’enquête menée par l’URPS montre que 40% des prises de rendez-vous en ligne ont lieu en dehors des heures d’ouverture des cabinets médicaux.


Via VAB Traductions, Lionel Reichardt / le Pharmageek
more...
No comment yet.
Rescooped by Dominique Godefroy from GAFAMS, STARTUPS & INNOVATION IN HEALTHCARE by PHARMAGEEK
Scoop.it!

Innovative UT pilot develops platform to help providers adopt digital health tools #esante #hcsmeufr #digitalhealth

Innovative UT pilot develops platform to help providers adopt digital health tools #esante #hcsmeufr #digitalhealth | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it

Healthcare is complicated. There's no getting around it. Which is why hospital leaders should be extremely skeptical of individual technologies that say they can fix it, says Lynda Chin, MD, executive director for real-world education detection and intervention at The University of Texas System and professor at Dell Medical School.

 

The challenges of healthcare are "so big and complex that no little solution is going to solve them," said Chin. "We do need these innovative technologies to fill the gaps – but what we don't talk enough about is how do you integrate that back. Because the patient is not going to get what they need if it's not integrated and connected through every other component."

 

In a recent article in the New England Journal of Medicine, Chin and her UT colleagues explained how they developed a pilot project to help build that patient-centric ecosystem of care.

The pilot involved and "Amazon-like" platform, "purpose-built for hosting market-available digital health products from a variety of companies," according to the article


Via Florian Morandeau, Lionel Reichardt / le Pharmageek
more...
Florian Morandeau's curator insight, October 16, 1:25 AM

The idea is to create a connected ecosystem of care, given that "no single device, app, or piece of data in isolation that will deliver benefits to patients."

Scooped by Dominique Godefroy
Scoop.it!

2018: AI Is Surging In Drug Discovery Market

2018: AI Is Surging In Drug Discovery Market | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it

The idea of using artificial intelligence (AI) to accelerate drug discovery process and boost a success rate of pharmaceutical research programs has inspired a surge of activity in this area over the last several years. In 2018, things are getting even “hotter” with the increase in the amount of partnerships, investments and other important events, summarized and grouped below into “mini-trends”.

1. Venture capital is pouring into AI-driven drug discovery startups

This year has been marked by an impressive number of fundraising deals among AI-driven drug discovery startups -- a clear indication of the “AI for drug discovery” space gaining some serious attractiveness for venture capitalists.

BenevolentAI

So far, a London-based BenevolentAI appears to be a leader of the year in terms of fundraising -- in April they closed a $115 M round, reaching a staggering $2 billion valuation mark. While met with certain degree of skepticism, this news and the current pace of research activity by the company undoubtedly puts BenevolentAI in a very strong position among competitors.

Atomwise

Atomwise, which was founded in 2012 and pioneered the use of deep neural networks for structure-based drug design, raised $45 M round A investment to advance its AI-driven drug discovery technology AtomNet. The company says it screens 10 million small molecules each day and uses AtomNet, which is utilizing deep learning algorithms, to analyze molecules and predict their potency as medications, toxicity, and side effects.

Insilico Medicine

A quite unique company on the list -- a US-based Insilico Medicine, which is the only one startup among its closest competitors which develops a “full-stack” artificial intelligence system based on generative adversarial networks (GANs), allowing for an “end-to-end” drug discovery process -- from basic biological modeling and biomarker development, to hit-molecule generation, lead optimization and pre-clinical validation of drug-candidates. In June, Insilico Medicine received an undisclosed amount of strategic investment from WuXi AppTec, bringing totally raised capital up to $20 M (according to Crunchbase).

Verge Genomics

Notably, just a month later, WuXi AppTec participated in a $32 M investment round for another AI-driven startup -- Verge Genomics. The latter uses machine learning and AI to develop therapeutics against Alzheimer's and Parkinson’s disease. Verge is also actively growing its database of patient genomic data -- allegedly, the company possesses one of the industry’s largest resources in this therapeutic area.

Owkin

New York - Paris based Owkin, founded in 2016 to apply machine learning for optimizing drug discovery process via better comprehending the overabundant biological data, raised its Round A of $11M in January to scale its technology platform Owkin Socrates. The platform can integrate molecular and imaging libraries with patient data to reveal patterns of biomarkers causing a disease, and the company is applying transfer learning to improve model performance where properly labeled data is scarce.

more...
No comment yet.
Scooped by Dominique Godefroy
Scoop.it!

Data security concerns could be delaying smart inhaler rollout

Data security concerns could be delaying smart inhaler rollout | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it
‘Smart’ or ‘connected’ inhalers are enhanced with the ability to collect and share data about their usage. A number of early players are already on the market and early trials across the globe are indicating that this can be an effective way of improving adherence.

Current smart inhalers enable patients and their healthcare provider to monitor how closely the prescribed treatment plan is being followed. As the sector matures, increased functionality, such as which parameters can be measured, is expected to follow. For example, devices that use acoustic sensors to monitor inhalation technique and provide feedback are already in development.

Michael Earl, Commercial Director at Bespak said, “Data shows that nearly all patients don’t always use their inhalers properly, and nearly two-thirds don’t always take their medication. Clearly there is a need to make inhalers more user-friendly to allow for better disease management. We know that increasing adherence to respiratory medication can more than halve hospital admissions. The cost saving implications and potential patient benefits are huge.”

Bespak has uncovered that 48% of chronic obstructive pulmonary disease (COPD) patients feel that device connectivity would have the most benefit if it could help in predicting exacerbations. Among professionals in the industry, improved patient engagement (44%) and improved health informatics (34%) are thought to be the areas where the technology can add the most value. 67% of industry participants in the research felt that connectivity would help with compliance of treatment regimes.

However, Bespak’s research revealed that despite 63% of the chronic COPD patients surveyed believing that connectivity would help in preventing the worsening of their respiratory condition, 59% voiced that they would not want a connected device. So why the apparent disconnect? Further questioning identified that security topped the list of concerns for many patients (59%), suggesting that a fear of data hacking has spread over from other industries.
more...
No comment yet.
Scooped by Dominique Godefroy
Scoop.it!

Aetna, CVS, Walgreens And Amazon May Finally Let Pharma Do What It Does Best

Aetna, CVS, Walgreens And Amazon May Finally Let Pharma Do What It Does Best | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it
Aetna, CVS, Walgreens, and Amazon are some of the most powerful words in healthcare. And in that context, the era of retail medicine is fast approaching. Much of this concept is build around the love affair with the customer that defines much of the retail marketplace today. Or, as some say, customer-centricity.

Today, there's a vast debate around the criticality of focusing on the customer and the emerging role of mega-companies such as Amazon and the newly government-approved merger of Aetna and CVS. Both are hot topics that seem to homogenize into the new healthcare dynamic that most seem to put forward as the " big idea" that will change the game.

Focus on the customer. Redefine the experience along the lines of the Apple store or The Four Seasons.

It all makes sense. The new role of "whatever-centricity" allows for a broken system to build things from the customer and move upward. With that newfound focus, we can reinvent healthcare by learning from the "business physicians of the day" like Steve Jobs, Warren Buffet, and Jeff Bezos. The democratization of healthcare is getting closer.

But there's another player in this complex set of moving parts that is hovering over these changes with a watchful and worried eye: the pharmaceutical industry. Seeking to reinvent itself too, big pharma has been quick to adopt the patient first strategy and proudly displays its perspective in just about every mission statement and tagline around. But pharma's nervous preoccupation with patient-centricity and its potential collision course with the retail giants may be the best thing that ever happened to this industry.

Big pharma and the even bigger retail giants appear to be moving to battle. The financial forces, the PBMs, the vocal consumers, and the marketing departments appear to align for the battle of healthcare. Most conversations seem to establish a zero-sum game where there will be a winner and a looser.
more...
No comment yet.
Scooped by Dominique Godefroy
Scoop.it!

AI in healthcare: Can AI solve the health tech puzzle of new drug discovery?

AI in healthcare: Can AI solve the health tech puzzle of new drug discovery? | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it
R&D is critical in the world of healthcare, but it is also tricky; progress is slow, and further progress is hampered by the way different researchers and drug developers work in silos, data is kept secret, locked away from the rest of the world. Can AI in healthcare come to the rescue?

Vas Narasimhan, CEO at Novartis, recently warned of a problem finding new data. In an interview with Bloomberg, he said that this lack of data has in part caused his initial enthusiasm for AI to turn more cautious.

This may yet prove to be the single biggest hurdle in applying AI in healthcare to help find cures to new diseases, extend life, and improve the quality of life.

Julien de Salaberry, CEO of Galen Growth Asia, a Singapore based organisation that is creating a $70 billion health tech ecosystem across Asia put it this way: “AI as a tool to aid research is still largely hype.”

He explains: “Its use is hampered largely because of the way data is held in silos and the interoperability of data is not there — everybody is hoarding data as if it was gold, and so the academic centres don’t speak to each other, the researchers don’t speak to each other, either.

“Everyone is building data, it’s growing faster than any other commodity on the planet, but no one is really sharing that data.”
more...
No comment yet.
Scooped by Dominique Godefroy
Scoop.it!

Exclusive: Remedy launches screening tool to uncover undiagnosed chronic illness

Exclusive: Remedy launches screening tool to uncover undiagnosed chronic illness | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it

San Francisco-based startup Remedy has launched an AI-powered tool to screen patients for their risk of chronic illness.

Dubbed Remedy Sentinel, the new platform aids the company’s care coordinators to assess and identify both clinical and sociodemographic risk factors for chronic illnesses like diabetes, COPD, chronic kidney disease, depression and congestive heart failure.

“We’re training our algorithm to think like a physician to empower non clinical staff on how to get information from a patient,” said CEO William Jack in a phone interview. “There’s important information that is generated outside of the four walls of the clinic that aren’t captured in EMR and claims data.”

According to Jack, traditional diagnostic and screening methods don’t delve deeply enough into the lifestyle and social factors that contribute to the risk for chronic disease. Alongside disease diagnosis, the company helps connect patients to resources to help manage their condition more effectively.

Remedy is also launching an associated pro-bono service that allows patients with providers or health plans not using the platform to apply for their own chronic disease screenings.

The company’s origins date back to the issues when Jack was misdiagnosed for his epilepsy and wanted to determine a better way to utilize more up-to-date data into the diagnostic process.

By targeting chronic disease, the company is focusing on the main cost drivers in the healthcare system and hoping to highlight potential health risks for patients before they get to a crisis point. An oft-cited statistic is that five percent of patients drive 95 percent of healthcare costs.

Based on an analysis of CDC and AHRQ data, the company claims that tens of millions of Americans are at potential risk of a chronic illness that they are unaware of, including 70 percent of patients with chronic kidney disease and 20 percent of patients with diabetes.

more...
No comment yet.
Scooped by Dominique Godefroy
Scoop.it!

Foundation Medicine, Novartis partner up on companion diagnostics in oncology

Foundation Medicine, Novartis partner up on companion diagnostics in oncology | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it

A company focused on next-generation sequencing-based diagnostics is partnering with a large Swiss drugmaker.

Foundation Medicine, based in Cambridge, Massachusetts, said Wednesday that it had formed a collaboration with Novartis. The development and commercialization partnership will involve Novartis using the diagnostics maker’s comprehensive genomic profiling assay, FoundationOne CDx, to develop companion diagnostics for its cancer drugs. FoundationOne CDx received Food and Drug Administration approval in November 2017. Fellow Swiss drugmaker Roche acquired the remaining shares of Foundation Medicine that it didn’t already own in June.

“It is imperative that we collaborate with all of the key stakeholders in oncology to accelerate patient access to personalized medicine,” Foundation Medicine Chief Business Officer Melanie Nallicheri said in a statement.

The partnership will also enable Foundation to expand into markets outside the US. In Japan, it is working with drugmaker Chugai and has submitted FoundationOne CDx for regulatory approval with the Ministry of Health, Labour and Welfare. The company said the move would allow cancer patients in Japan to have access to approved targeted therapies, immunotherapies and clinical trials.

more...
No comment yet.
Scooped by Dominique Godefroy
Scoop.it!

Virtual reality for stroke patients one step closer thanks to £400k funding

Virtual reality for stroke patients one step closer thanks to £400k funding | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it
A partnership involving an NHS hospital in Chester has received more than £400,000 in funding so it can explore the possibility of using virtual reality (VR) to help stroke patients.

The University of Chester’s medical graphics team and the stroke department at the Countess of Chester Hospital believe VR can be used to help people following a stroke.

In particular, the organisations are exploring how a VR headset could be used to give patients the ability to practice and relearn daily activities, such as putting bread into a toaster.

A funding grant of £453,000 has been awarded to the project from the government’s Digital Health Technology Catalyst (DHTC) programme.

Nigel John, from the University of Chester, said: “Our aim is to reduce the duration and cost of long-term care by enabling intensive rehabilitation both in hospital and in the home, using affordable technology. The VR stroke programmes will adapt to each user’s needs and can be operated with minimal supervision, meaning they do not need to rely on family and carers.

“Patients will be able to measure how well their cognitive abilities are improving, building confidence in their ability to perform everyday tasks and reducing the psychological trauma often associated with the condition.”
more...
No comment yet.
Scooped by Dominique Godefroy
Scoop.it!

« Faites confiance aux patients ! » Quelle nouveauté pour quelle transformation en France ? ExpériencePatient.fr lance son 1er baromètre

« Faites confiance aux patients ! » Quelle nouveauté pour quelle transformation en France ? ExpériencePatient.fr lance son 1er baromètre | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it

#faitesconfianceauxpatients

Leur expérience va transformer nos services de santé. Apprendre à recueillir et analyser cette expérience devient un enjeu stratégique pour répondre aux besoins des personnes et orienter les priorités des professionnels. » Qu’est-ce qui se cache derrière le slogan prometteur et méritant de l’Institut Français Expérience Patient ?

Pour y répondre, l’institut de l’Expérience Patient, fondé par Amah KOUEVI, a organisé le 4 octobre 2018 une rencontre à l’auditorium de cardiologie de la Pitié Salpétrière, sur le thème :
« L’expérience patient made in USA, un exemple à suivre ? »

Pour compléter son diaporama en ligne, et diffuser son appel « faites confiance aux patients », je propose de mettre en perspective les exposés et retours de la salle en quatre étapes :

- partir de la définition de l’expérience patient, pour mieux la comprendre et préciser : expérience patient, de quoi parlons-nous ?
- éclairer la dynamique internationale en route : quelle est donc la nouveauté de la nouveauté expérience patient ?
- observer comment elle se déploie aux US, notamment à la Cleveland Clinic, 2ème meilleur hôpital du pays : patient first, medical second
- voir ce que nous disent ces modèles américains issus d’une culture médicale

more...
No comment yet.
Rescooped by Dominique Godefroy from PATIENT EMPOWERMENT & E-PATIENT
Scoop.it!

Plateforme de signalement des effets indésirables : un premier bilan  #esante #hcsmeufr

Plateforme de signalement des effets indésirables : un premier bilan  #esante #hcsmeufr | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it
Il y a un an, le ministère de la santé mettait en place la plateforme signalement-sante.gouv.fr à destination des patients, des consommateurs et des professionnels de santé pour « renforcer la vigilance en matière de sécurité sanitaire et simplifier les démarches de signalement ».
 
Elle permet de déclarer des événements indésirables liés aux médicaments, aux dispositifs médicaux, aux « produits de la vie courante », aux actes de soin, aux produits de tatouage, aux cosmétiques, aux compléments alimentaires et enfin aux substances psychoactives légales ou illégales (en dehors de l’alcool et du tabac).
 
Ce premier anniversaire a été l’occasion pour la Direction générale de la santé (DGS) d’établir un premier bilan.
 
Au total, 85 % des signalements sont le fait de non-professionnels de santé et 45 000 signalements ont été recensés. Cependant, la quasi-totalité des signalements d’événements indésirables graves associés à des soins proviennent d’établissements de santé.
 
« La pharmacovigilance et la matériovigilance représentent respectivement 90 % et 5 % des signalements chez les usagers, alors que les professionnels de santé utilisent principalement le portail pour signaler des cas de pharmacovigilance (40 %), des évènements indésirables graves associés à des soins (28 %) et des cas de matériovigilance (14 %) » précise la DGS qui souligne que « le portail s’avère fortement utilisé par les usagers et constitue un réel élément de démocratie sanitaire ».

Via Lionel Reichardt / le Pharmageek
more...
No comment yet.
Rescooped by Dominique Godefroy from Social Media and Healthcare
Scoop.it!

Facebook's Head of Health Wants Medical Researchers to Utilize Patient's Social Life Data

Facebook's Head of Health Wants Medical Researchers to Utilize Patient's Social Life Data | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it

Facebook’s head of health research has argued that doctors need information patient’s social lives. In a conference on Wednesday, Dr. Freddy Abnousi spoke about the lack of data in this regard.

“The primary driver of health outcomes in the United States are social and behavioral variables,” he said at the Manoca Summit in Minneapolis. “Really understanding what these social determinants of health care should be our primary area of focus.”
Abnousi didn’t outright say it, but the implication is that hospitals could share data with it or vice versa. In fact, Abnousi led a secret research project with that exact goal earlier in the year. He sought anonymized patient data from hospitals to match with social media users via hashing.

However, the project was put on hold before any deals were signed. Facebook came under huge scrutiny after the Cambridge Analytica scandal and would have struggled to argue that it could keep such data safe.

An Unnecessary Solution?

Abnousi seems passionate about this despite the recent compromise of up to 50 million Facebook accounts. However, some professionals are skeptical about how much use the social media would be.

Facebook’s previous approach was to work with medical groups to share the data of their most vulnerable patients.

 

“There are more humanistic and reliable ways to acquire this information,” said Dan Gebremedhin, physician and a health investor at Flare Capital Partners, at the time.  “How about asking the patient, their healthcare proxy, or the primary care provider? Given the variability in user activity on Facebook, I’m not sure that this information would be correlated and accurate at the patient level.”

 

There are some concerns that the company wants to utilize such data to deliver things such as medical ads. However, even without that, it’s unclear how anonymous the data would be.

A previous study of ‘anonymous’ Washing State healthcare data found that it could be correlated with newspaper stories. This netted a correct identification 43% of the time. It’s not hard to imagine why users wouldn’t trust a company that has leaked their data several times.

 

Via Plus91
more...
No comment yet.
Scooped by Dominique Godefroy
Scoop.it!

L’ordre des médecins s’oppose à la publicité pour la télémédecine

L’ordre des médecins s’oppose à la publicité pour la télémédecine | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it
Le Conseil national de l’ordre des médecins a décidé de mettre en demeure la société Qare pour qu’elle cesse la diffusion d’encarts publicitaires pour ses services de télémédecine. Des publicités que le Conseil juge fallacieuses.

« Satisfaits et remboursés ». C’est le titre de la publicité présentée par la société Qare dans le Journal du dimanche pour promouvoir son service de télémédecine. L’encart a été publié le 15 septembre, date à laquelle l’Assurance maladie a commencé à prendre en charge la télémédecine. Une publicité qui n’est pas du goût du Conseil national de l’ordre des médecins qui a annoncé, dans un communiqué publié lundi dernier, avoir pris la décision, lors de sa session plénière du 27 septembre, de mettre en demeure la société Qare de cesser la publication de ses encarts promotionnels.

Bien qu’il se félicite de l’essor de la télémédecine et de la téléconsultation, l’Ordre indique vouloir éviter que ces nouvelles pratiques entrainent une « ubérisation » de la médecine. Il insiste : « le développement d’offres de télémédecine ne saurait signifier un affranchissement des règles d’exercices de la profession ». Aussi, la télémédecine doit donc respecter le principe d’interdiction de la publicité en matière médicale.

Le Conseil estime également que ces publicités sont fallacieuses, quand elles laissent croire aux usagers de Qare que leurs dépenses de télémédecine seront remboursées par l’Assurance maladie. Or, l’accord conclu entre l’Assurance maladie et les syndicats de médecin sur la prise en charge de la télémédecine n’inclut justement pas les services de télémédecine créés par des assurances et des sociétés privées, dont Qare, au grand dam de ces derniers qui investissent de plus en plus dans ces plateformes de télémédecine.
more...
No comment yet.
Scooped by Dominique Godefroy
Scoop.it!

Remote patient monitoring via smartphone cuts one-week post-partum visits by 57%

Remote patient monitoring via smartphone cuts one-week post-partum visits by 57% | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it
Historically, at the University of Pittsburgh Medical Center Magee-Womens Hospital in Pittsburgh, when a patient has been discharged from the hospital and has had a hypertensive disorder during her pregnancy or postpartum period, it recommended follow-up within a week to the primary OB provider for a blood pressure check.

Patients are sometimes sent home on new medications or continuing to take a medication they were prescribed during the pregnancy related to hypertension diagnosis. These patients are given instructions and education regarding signs and symptoms that would alert them to call their OB or come back to the emergency department.

It has not been a standard of care to ask this population of patients to check their blood pressure regularly and report it back during the weeks following a delivery. Patients experiencing and needing treatment for a hypertensive crisis is the most common reason for readmission to UPMC Magee-Womens Hospital.

These women also are at an increased risk for developing some type of cardiovascular disease later in life because of the development during their pregnancy. Therefore, follow-up with their primary care physician is a goal that the hospital felt needed to be addressed.
more...
No comment yet.
Scooped by Dominique Godefroy
Scoop.it!

Google AI algorithm to help with metastatic breast cancer diagnosis

Google AI algorithm to help with metastatic breast cancer diagnosis | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it
Google's artificial intelligence team has developed an algorithm that's like "spell check" for pathologists, the doctors responsible for diagnosing cancer patients through images of their cells.


In two papers published Friday, Google found that its algorithm complemented what the pathologists were able to pick up from the images in terms of determining how much patients' cancers had spread in their lymph node tissue.


"This represents a demonstration that people can work really well with AI algorithms than either one alone," Yun Liu, a member of the Google AI team and an author on the papers, told Business Insider.

more...
No comment yet.
Scooped by Dominique Godefroy
Scoop.it!

Santé et IA : les Gafa et les start-up dans la course

Santé et IA : les Gafa et les start-up dans la course | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it

Les géants du Web s'intéressent de près à la santé, Google en tête, IBM n'est pas très loin, mais les start-up ont aussi leur carte à jouer.

Et si les Gafa devenaient aussi des géants de la santé ? Google a tenté d'enfiler la blouse blanche il y a plus de dix ans. Après l 'échec de Google Health , son dossier médical en ligne abandonné en 2012, la firme est revenue en force avec sa filiale DeepMind Health, en faisant ce qu'elle sait faire de mieux : collecter et traiter les données. En l'occurrence celles de patients d'hôpitaux, notamment britanniques.

Les choses ont toutefois été plus difficiles que prévu avec le Royal Free Hospital Trust, qui lui permettait d'accéder à l'historique médical de 1,6 million de patients. L'accord a été dénoncé quand les autorités britanniques ont constaté que ces données n'avaient pas été anonymisées et avaient été utilisées dans un cadre plus large que prévu.

Mais Alphabet, la maison mère de Google, a plusieurs fers au feu. Le projet Baseline, porté par sa filiale Verily, a l'ambition de « cartographier » la santé humaine, en recueillant les données de santé de 10.000 volontaires grâce à des objets connectés. Dernière initiative en date liée à la galaxie Alphabet, la start-up Cityblock, dans laquelle a investi une autre filiale, Sidewalk Labs, vise à offrir des services médicaux et à faire de la prévention en direction des titulaires des minima sociaux américains.

Les autres géants du Web ne sont pas inactifs. Amazon se lance dans l'assurance santé, et Facebook AI Research (Fair), après avoir recruté Yann LeCun, l'un des pères du « deep learning », a embauché en début d'année Jérôme Pesenti, un ancien responsable du programme Watson d'IBM. Apple confirme aussi son intérêt pour la santé avec sa montre Apple Watch Series 4, le premier appareil grand public doté d'un capteur et d'un algorithme susceptibles de détecter un incident cardiaque.

more...
No comment yet.
Scooped by Dominique Godefroy
Scoop.it!

Hennebont. Un robot innovant pour les victimes d’AVC

Hennebont. Un robot innovant pour les victimes d’AVC | eHealth mHealth HealthTech innovations - Marketing Santé innovant | Scoop.it
Répondant à un appel à projets « Innovation en santé » de l’Agence régionale de santé (ARS) de Bretagne, le robot Reaplan a trouvé preneur sur le sol breton. Acquisition du Groupe Hospitalier Bretagne Sud (GHBS), la machine a été inaugurée, vendredi. L’enjeu ? Optimiser la rééducation des patients victimes d’un accident vasculaire cérébral (AVC).

Grand écran, joystick : il pourrait ressembler à s’y méprendre à une nouvelle console de jeux vidéo haute technologie. Le robot s’adresse aux patients (adultes ou de pédiatrie) atteints de troubles neurologiques ou traumatologiques. Scratchs serrés, la main positionnée sur le joystick : le programme propose trois modes d’intensité (passif, actif aidé, actif) et variation de jeux (circuits à suivre, recettes virtuelles). Les gestes (calqués sur ceux du quotidien) sont relayés et enregistrés sur le superviseur, permettant d’analyser au plus juste l’évolution. « L’activité ? Environ 500 mouvements par séance, contre moins de 100 avec une séance traditionnelle. Plus on est dans l’intensité, plus le cerveau est stimulé pour créer un réseau de neurones », explique Fabien Nicolet,ergothérapeute. Si le robot est initialement voué aux patients victimes d’AVC, il se montre également efficace pour d’autres pathologies (type Parkinson, syndrome de Guillain-Barré). « C’est une matière grise qui évoluera une fois que l’on aura plus de recul. Elle a vocation à profiter au plus grand nombre », reconnaît Éric Hanesse, directeur de Axinesis, la start-up belge qui a mis au point le robot.
more...
No comment yet.